Heller Professor Receives Special Recognition Award

October 18, 2006

Professor Donald S. Shepard has received a “Special Recognition Award” from the Mental Health and Substance Abuse Corporations of Massachusetts, Inc. (MHSACM). Prof. Shepard and the Honorable Edward M. Kennedy, Senior Senator from Massachusetts, were the two individuals given these awards at the organization’s annual Provider Day Celebration on October 10, 2006.

The citation for Prof. Shepard’s award reads, in part: “Every now and then, an individual or organization has played a role so special to the mission and course of MHSACM and its members…Dr. Donald Shepard is one of those special individuals for MHSACM. Many of you may know him best as the Brandeis researcher who has conducted significant studies on the cost-effectiveness of substance abuse treatment and the unmet need for substance abuse treatment in Massachusetts, and contributed to a review of the Massachusetts Behavioral Health Program. In late 2005, Dr. Shepard’s talents and brilliant analytic skills became even more evident to us when, along with the support of Brandeis colleague Matthew Neuman, M.Sc., and Sara Hartman of MHSACM, he prepared an initial comparative analysis of the range of the five MassHealth managed care organizations [at MHSACM’s request]. He subsequently presented his findings before a hearing of the state’s Joint Committee on Mental Health and Substance Abuse.”

Also in the News

Judge Kavanaugh’s Supreme Court Nomination Could Put the Americans With Disabilities Act in Danger

July 26, 2018

In Rewire.News, Robyn Powell says 28-years-ago, the Americans with Disabilities Act (ADA) became law. But Judge Kavanaugh’s Supreme Court Nomination nomination could threaten it.

Inside Google’s Shadow Workforce

July 25, 2018

In Bloomberg, David Weil says we have allowed businesses to really sever their responsibility for more and more of the people who create value.

The Health 202: ACA’s medical device tax once again on the chopping block

July 25, 2018

In the Washington Post, Andrew Kolodny says it was interesting that Purdue Pharma seemed to initially acknowledge the risk of opioid prescriptions.

News Archive →